NEW YORK CITY DEPARTMENT OF
HEALTH AND MENTAL HYGIENE
Michelle Morse, MD, MPH
Acting Health Commissioner

December 27, 2024

Re: Update on STOMP Trial and Tecovirimat Availability

Dear Colleagues,

On December 10, 2024, the Centers for Disease Control and Prevention (CDC) announced the conclusion of enrollment for the STOMP trial (Study of Tecovirimat for Mpox). Findings from two clinical trials confirm that tecovirimat is safe; however, it did not shorten the duration of mpox lesion resolution.

Tecovirimat can still be accessed through the CDC's Expanded Access Investigational New Drug protocol (EA-IND) for patients who meet criteria that include those who:

- Are severely immunocompromised
- Have life-threatening mpox symptoms
- Have specific skin conditions
- Are pregnant, breastfeeding, or younger than 18 years of age

We recommend the use of tecovirimat in combination with other antiviral treatments, such as VIGIV, brincidofovir, and cidofovir, in consultation with the CDC.

Oral tecovirimat will no longer be available in New York City through Pharmex Pharmacy. Providers may request tecovirimat and discuss additional treatment options by calling the CDC Emergency Operations Center (EOC) at 770-488-7100 or emailing poxvirus@cdc.gov.

For other mpox-related questions, please contact the NYC Health Department Provider Access Line at 866-692-3641.

Importance of Vaccination: Providers are urged to continue emphasizing the importance of mpox vaccination for eligible individuals, particularly those at elevated risk of severe outcomes. For facilities that do not provide mpox vaccinations, direct patients to vaccinefinder.nyc.gov to locate a vaccination site.

Sincerely,

Celia Quinn, MD, MPH
Deputy Commissioner
Division of Disease Control

Preeti Pathela, DrPH, MPH
Executive Director, Sexually Transmitted Infections Program
Bureau of Hepatitis, HIV, and Sexually Transmitted Infections